Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 15/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189776 | 0.94 | ALDH1A1 (0.56) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL12658 | 0.94 | ALDH1A1 (0.56) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL12449683 | 0.94 | ALDH1A1 (0.56) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL26743234 | 0.91 | ALDH1A1 (0.53) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL24480309 | 0.89 | ALDH1A1 (0.39) | ALDH1A1ADRA1ASMN1; SMN2 | |
| SCHEMBL24185415 | 0.85 | ALDH1A1 (0.44) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL27292954 | 0.85 | ALDH1A1 (0.46) | ALDH1A1ADRA1ASMN1; SMN2 | |
| SCHEMBL26743104 | 0.84 | ALDH1A1 (0.41) | ALDH1A1ADRA1ASMN1; SMN2 | |
| SCHEMBL22703922 | 0.82 | ALDH1A1 (0.46) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 | |
| SCHEMBL12717685 | 0.82 | ALDH1A1 (0.46) | ALDH1A1ADRA1AL3MBTL1L3MBTL3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023131167-A1 | COMPOUND FOR INHIBITING AND DEGRADING IRAK4, AND PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 海思科医药集团股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | ALDH1A1 861/4885ADRA1A 274/4885L3MBTL1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.